Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for ...

Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA ® (darolutamide; n=55) ...

Discover the essential techniques for validating and cleaning JSON data, ensuring data integrity and proper formatting for various applications and APIs.

The Tigers survived and advanced in the regional with a hard fought win over NC State Saturday, and they will have to do it ...

WASHINGTON (AP) — A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of ...